Exelixis And Bristol-Myers Squibb Report New Phase 2 Data For XL184 In Patients With The Most Common And Aggressive Form Of Brain Cancer

Exelixis, Inc. and Bristol-Myers Squibb Company reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.